



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

David H. Lynch, Luis Borges, Robert E.
Miller and Charles R. Maliszewski

Docket No.: 2836-C

Group Art Unit: 1644

Serial No: 09/444,027

Examiner: P. Gambel

Filed: November 19, 1999

For: DENDRITIC CELL STIMULATORY FACTOR

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND REPLY

Dear Sir:

In response to the Office action, having a mailing date of June 19, 2001, Applicants respectfully submit the following Amendment and Reply. A Petition for a one-month extension of time and requisite fee are included extending the date of response to October 19, 2001. In view of the following amendments and accompanying remarks, Applicants respectfully request reconsideration and allowance of the pending claims. Applicants will address each of the Examiner's concerns in the order presented in the Office Action.

Kindly amend the specification as follows:

In the Specification:

Please replace the current title with the following:

-- USE OF FLT3-LIGAND IN COMBINATION THERAPY TO AUGMENT

01/14/2002 IMMUNE RESPONSES 09/444,027

01 FC:103 18.00 CH

Please replace the paragraph at page 1 under the heading "Related Applications" with the following rewritten paragraph:

This application is a continuation-in-part of U.S. Application Serial No. 09/154,903, filed September 17, 1998, now abandoned, which is a continuation-in-part of U.S. Application Serial No. 08/725,540, filed October 3, 1996, now abandoned, which is continuation-in-part of U.S. Application Serial No. 08/539,142, filed October 4, 1995, now abandoned.

#97A
HARRY
Jan. 12, 2002

RECEIVED
JAN 04 2002
TECH CENTER 1600/2900

21